000302141 001__ 302141
000302141 005__ 20250629021209.0
000302141 0247_ $$2doi$$a10.1186/s41687-025-00907-z
000302141 0247_ $$2pmid$$apmid:40536596
000302141 0247_ $$2pmc$$apmc:PMC12179011
000302141 0247_ $$2altmetric$$aaltmetric:178327383
000302141 037__ $$aDKFZ-2025-01259
000302141 041__ $$aEnglish
000302141 082__ $$a610
000302141 1001_ $$aSweegers, Maike G$$b0
000302141 245__ $$aDevelopment of a unified system for assessing health related quality of life across the cancer care continuum: the EUonQoL Delphi study to identify priorities for quality of life domains.
000302141 260__ $$aLondon$$bSpringerOpen$$c2025
000302141 3367_ $$2DRIVER$$aarticle
000302141 3367_ $$2DataCite$$aOutput Types/Journal article
000302141 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1750686555_12696
000302141 3367_ $$2BibTeX$$aARTICLE
000302141 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302141 3367_ $$00$$2EndNote$$aJournal Article
000302141 520__ $$aCancer and cancer treatment have a major impact on health related quality of life (HRQoL). To improve the assessment of HRQoL in patients with cancer and evaluate the impact of policy interventions, the European Oncology Quality of Life (EUonQoL) project aims at developing a digital, patient centred system to assess HRQoL based on evaluations and preferences of cancer patients and survivors: the EUonQoL-kit.Patients across the cancer care continuum, healthcare professionals and researchers from six European countries (Denmark, France, Germany, Italy, The Netherlands and United Kingdom) were asked to rate the importance of 44 pre-selected HRQoL subdomains over a maximum of three Delphi survey rounds. We evaluated the importance of HRQoL subdomains for three target populations: patients undergoing active treatment, cancer survivors and patients receiving palliative care. The results were discussed during a consensus meeting.96 patients and 59 healthcare professionals participated in the Delphi study. After three rounds, consensus was reached for 20 subdomains: ability to work, communication with healthcare professionals, diarrhoea, fatigue, fear of recurrence, global health status, impact of treatment side effects, impact on children/family, insomnia, instrumental activities of daily living, maintaining independence, mobility, nausea, overall quality of life, pain, partner relationship, social activity limitations, social isolation, symptom awareness and uncertain prognosis. The subdomains pain and fear of recurrence were rated as important for all three target populations.Subdomains that were considered important for the assessment of HRQoL in patients with cancer can be summarised into: physical symptoms, mobility & activity, future outlook, social roles & activities, family & relationships, social isolation, self-efficacy, overall HRQoL, and healthcare experience. The importance of the subdomains differed for patients in different phases of the cancer care continuum. These findings were used for the creation of the first version of the EUonQoL-Kit, as a base for its further development.
000302141 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000302141 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302141 650_7 $$2Other$$aCancer
000302141 650_7 $$2Other$$aDelphi study
000302141 650_7 $$2Other$$aPatient centred research
000302141 650_7 $$2Other$$aPatient-reported outcome measures
000302141 650_7 $$2Other$$aQuality of life
000302141 650_2 $$2MeSH$$aHumans
000302141 650_2 $$2MeSH$$aQuality of Life: psychology
000302141 650_2 $$2MeSH$$aDelphi Technique
000302141 650_2 $$2MeSH$$aNeoplasms: therapy
000302141 650_2 $$2MeSH$$aNeoplasms: psychology
000302141 650_2 $$2MeSH$$aMale
000302141 650_2 $$2MeSH$$aFemale
000302141 650_2 $$2MeSH$$aMiddle Aged
000302141 650_2 $$2MeSH$$aEurope
000302141 650_2 $$2MeSH$$aAdult
000302141 650_2 $$2MeSH$$aContinuity of Patient Care
000302141 650_2 $$2MeSH$$aAged
000302141 650_2 $$2MeSH$$aCancer Survivors: psychology
000302141 650_2 $$2MeSH$$aSurveys and Questionnaires
000302141 650_2 $$2MeSH$$aPatient Reported Outcome Measures
000302141 650_2 $$2MeSH$$aPalliative Care
000302141 7001_ $$ade Jongh, Esther$$b1
000302141 7001_ $$aBedding, Christopher$$b2
000302141 7001_ $$aNicklin, Emma$$b3
000302141 7001_ $$0P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDoege, Daniela$$b4$$udkfz
000302141 7001_ $$aAlfieri, Sara$$b5
000302141 7001_ $$aGangeri, Laura$$b6
000302141 7001_ $$aScacciati, Bianca$$b7
000302141 7001_ $$aCaraceni, Augusto$$b8
000302141 7001_ $$aBrunelli, Cinzia$$b9
000302141 7001_ $$aBredart, Anne$$b10
000302141 7001_ $$aRojas-Concha, Leslye$$b11
000302141 7001_ $$aPappot, Helle$$b12
000302141 7001_ $$aApolone, Giovanni$$b13
000302141 7001_ $$aBos, Nanne$$b14
000302141 7001_ $$aCiliberto, Gennaro$$b15
000302141 7001_ $$aCouespel, Norbert$$b16
000302141 7001_ $$aFerrer, Montse$$b17
000302141 7001_ $$aKaasa, Stein$$b18
000302141 7001_ $$aLombardo, Claudio$$b19
000302141 7001_ $$aPietrobon, Ricardo$$b20
000302141 7001_ $$aPravettoni, Gabriella$$b21
000302141 7001_ $$aSirven, Aude$$b22
000302141 7001_ $$aVachon, Hugo$$b23
000302141 7001_ $$aGroenvold, Mogens$$b24
000302141 7001_ $$aFranzoi, Maria Alice$$b25
000302141 7001_ $$aVelikova, Galina$$b26
000302141 7001_ $$aGilbert, Alexandra$$b27
000302141 7001_ $$avan de Poll-Franse, Lonneke V$$b28
000302141 773__ $$0PERI:(DE-600)2906081-3$$a10.1186/s41687-025-00907-z$$gVol. 9, no. 1, p. 70$$n1$$p70$$tJournal of patient-reported outcomes$$v9$$x2509-8020$$y2025
000302141 909CO $$ooai:inrepo02.dkfz.de:302141$$pVDB
000302141 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000302141 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000302141 9141_ $$y2025
000302141 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ PATIENT-REP OUTCOM : 2022$$d2024-12-28
000302141 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000302141 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000302141 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:42:06Z
000302141 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:42:06Z
000302141 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double anonymous peer review$$d2024-04-10T15:42:06Z
000302141 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-04-10T15:42:06Z
000302141 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000302141 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-28
000302141 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000302141 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-28
000302141 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-28
000302141 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-28
000302141 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000302141 980__ $$ajournal
000302141 980__ $$aVDB
000302141 980__ $$aI:(DE-He78)C071-20160331
000302141 980__ $$aUNRESTRICTED